Altimmune Inc (NAS:ALT)
$ 7.89 0.19 (2.47%) Market Cap: 559.42 Mil Enterprise Value: 364.48 Mil PE Ratio: 0 PB Ratio: 3.23 GF Score: 30/100

Altimmune Inc at Goldman Sachs Healthcare Conference Transcript

Jun 14, 2023 / 11:00PM GMT
Release Date Price: $4.05 (+1.25%)
Corinne Jenkins
Goldman Sachs Group, Inc., Research Division - VP

Good afternoon, everyone, and welcome to the session with Altimmune. We are fortunate to have Vipin Garg and Scott Harris here from the team.

Questions & Answers

Corinne Jenkins
Goldman Sachs Group, Inc., Research Division - VP

Maybe first, we could just start with an overview of the company and with a particular focus on what you view as key value drivers over the next, let's call it, 12 to 24 months.

Vipin K. Garg
Altimmune, Inc. - President, CEO & Director

Okay. Yes. Perfect. Thank you for having us. So at Altimmune, we are developing peptide-based therapeutics for obesity and for liver diseases. Our most advanced asset is pemvidutide, which is a GLP-1 glucagon dual receptor agonist that we are developing for obesity and for NASH. And of course, we talk more about that. We also have immunotherapeutics and other peptide-based therapeutics that we're developing for hepatitis B.

For both of these programs, we're making

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot